News
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...
Sarah Michelle Gellar revealed former ‘Buffy the Vampire Slayer’ stars’ kids auditioned for the revival, shocking Alyson ...
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...
Microsoft launches Discovery platform that uses agentic AI to compress years of scientific research into days, transforming R&D across pharmaceuticals, materials science, and semiconductor industries.
Explore more
What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.
Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...
8h
Daily Voice on MSN25-Year-Old Microbiologist Shot Dead On PA Sidewalk; Boyfriend Charged With Murder: DAA 25-year-old woman was shot and killed on a West Conshohocken sidewalk early Sunday morning, and her boyfriend has been ...
The clinical trial for the potential vaccine, VLA15, began in August 2022. Stage 3 trials got underway in late 2023, ...
9h
Zacks Investment Research on MSNGSK or ACAD: Which Is the Better Value Stock Right Now?Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more ...
Microsoft Corp. today announced the launch of Microsoft Discovery, a new enterprise-grade artificial intelligence platform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results